Rational designs of in vivo CRISPR-Cas delivery systems

Cong-Fei Xu¹, Guo-Jun Chen², Ying-Li Luo³, Yue Zhang⁴, Gui Zhao⁵, Zi-Dong Lu³, Anna Czarna³, Zhen Gu⁶, Jun Wang⁷

Affiliations

¹ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China.
² Department of Bioengineering, California Nanosystems Institute, University of California, Los Angeles 90095, USA; Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Center for Minimally Invasive Therapeutics, University of California, Los Angeles 90095, USA.
³ Institutes for Life Sciences, School of Medicine, South China University of Technology, Guangzhou 510006, PR China.
⁴ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China; Key Laboratory of Biomedical Engineering of Guangdong Province, and Innovation Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, PR China.
⁵ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China; Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China University of Technology, Guangzhou 510006, PR China.
⁶ Department of Bioengineering, California Nanosystems Institute, University of California, Los Angeles 90095, USA; Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Center for Minimally Invasive Therapeutics, University of California, Los Angeles 90095, USA. Electronic address: guzhen@ucla.edu.
⁷ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China; National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, PR China; Key Laboratory of Biomedical Engineering of Guangdong Province, and Innovation Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, PR China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510005, PR China. Electronic address: mcjwang@scut.edu.cn.

PMID: 31759123
DOI: 10.1016/j.addr.2019.11.005

Review

Rational designs of in vivo CRISPR-Cas delivery systems

Cong-Fei Xu et al. Adv Drug Deliv Rev. 2021 Jan.

. 2021 Jan:168:3-29.

doi: 10.1016/j.addr.2019.11.005. Epub 2019 Nov 21.

Authors

Cong-Fei Xu¹, Guo-Jun Chen², Ying-Li Luo³, Yue Zhang⁴, Gui Zhao⁵, Zi-Dong Lu³, Anna Czarna³, Zhen Gu⁶, Jun Wang⁷

Affiliations

¹ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China.
² Department of Bioengineering, California Nanosystems Institute, University of California, Los Angeles 90095, USA; Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Center for Minimally Invasive Therapeutics, University of California, Los Angeles 90095, USA.
³ Institutes for Life Sciences, School of Medicine, South China University of Technology, Guangzhou 510006, PR China.
⁴ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China; Key Laboratory of Biomedical Engineering of Guangdong Province, and Innovation Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, PR China.
⁵ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China; Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China University of Technology, Guangzhou 510006, PR China.
⁶ Department of Bioengineering, California Nanosystems Institute, University of California, Los Angeles 90095, USA; Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Center for Minimally Invasive Therapeutics, University of California, Los Angeles 90095, USA. Electronic address: guzhen@ucla.edu.
⁷ Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 510006, PR China; National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, PR China; Key Laboratory of Biomedical Engineering of Guangdong Province, and Innovation Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, PR China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510005, PR China. Electronic address: mcjwang@scut.edu.cn.

PMID: 31759123
DOI: 10.1016/j.addr.2019.11.005

Abstract

The CRISPR-Cas system initiated a revolution in genome editing when it was, for the first time, demonstrated success in the mammalian cells. Today, scientists are able to readily edit genomes, regulate gene transcription, engineer posttranscriptional events, and image nucleic acids using CRISPR-Cas-based tools. However, to efficiently transport CRISPR-Cas into target tissues/cells remains challenging due to many extra- and intra-cellular barriers, therefore largely limiting the applications of CRISPR-based therapeutics in vivo. In this review, we summarize the features of plasmid-, RNA- and ribonucleoprotein (RNP)-based CRISPR-Cas therapeutics. Then, we survey the current in vivo delivery systems. We specify the requirements for efficient in vivo delivery in clinical settings, and highlight both efficiency and safety for different CRISPR-Cas tools.

Keywords: CRISPR-Cas; Drug delivery; Genome editing; Nanomedicine.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Research Materials
- Addgene Non-profit plasmid repository

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Rational designs of in vivo CRISPR-Cas delivery systems

Affiliations

Rational designs of in vivo CRISPR-Cas delivery systems

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials